Analyst Ratings for Atrium Therapeutics (RNA)
RNA Rating Summary
RNA Price Target Summary
- Highest: $96.00 (Cantor Fitzgerald)
- Lowest: $25.00 (Leerink)
- Average: $63.50
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$63.50 (+413.8%)
* Over Last 12-Mos
Rating Score: 5.2 / 10
Percentile Rank: 56%
Avg. $ Target:
$63.50 (+413.8%)
* Over Last 12-Mos
Rating Score: 5.2 / 10
Percentile Rank: 56%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/15/2026 | Leerink | Joseph Schwartz | New Coverage | Outperform (N/A) |
25.00 (N/A) |
13.27 (12.36) |
-6.86% | Details |
| 3/10/2026 | Wells Fargo | N/A | New Coverage | Overweight (N/A) |
25.00 (N/A) |
14.79 (12.36) |
-16.43% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
